Ozempic is Novo Nordisk's brand of semaglutide for type 2 diabetes. FDA-approved 2017 for T2D; expanded 2020 for CV risk reduction in T2D + CVD and January 2025 for chronic kidney disease in T2D. Weekly subcutaneous injection.
At a glance
- Generic name: semaglutide
- Manufacturer: Novo Nordisk
- List price: not re-checked in October 2026; see the manufacturer's pricing page
- Cash-pay program: NovoCare patient assistance
FDA-approved indications
- Type 2 diabetes (2017)
- CV risk reduction in T2D + established CVD (2020)
- Reducing kidney-disease progression and CV death in T2D with chronic kidney disease (January 2025; basis: FLOW)
Standard dosing
- Start: 0.25 mg/wk × 4 wk
- Titration: 0.5 → 1.0 → 2.0 mg
- Maintenance: 0.5–2.0 mg weekly